Showing results (1311-1320 of 2,037) with videos related to

Sort By:
Pageof 204
Nuklearmedizin. Nuclear Medicine|October 31, 2006
201Tl scintigraphy in the evaluation of palpable and nonpalpable breast lesions: correlation with mammography and ultrasonographyG Vural, T Atasever, A Ozdemir, et al.
Nuklearmedizin. Nuclear Medicine|October 18, 2006
Gender dependent rate of metabolism of the opioid receptor-PET ligand [18F]fluoroethyldiprenorphineG Henriksen, M E Spilker, T Sprenger, et al.
Nuklearmedizin. Nuclear Medicine|October 18, 2006
What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?M Gotthardt, C Rubner, A Bauhofer, et al.
Nuklearmedizin. Nuclear Medicine|October 18, 2006
Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?S Dunkelmann, H Künstner, E Nabavi, et al.
Nuklearmedizin. Nuclear Medicine|June 22, 2005
Myocardial perfusion/metabolism mismatch and ventricular arrhythmias in the chronic post infarction stateB J Krause, T D Poeppel, M Reinhardt, et al.
Nuklearmedizin. Nuclear Medicine|June 22, 2005
Direct injection of (188)Re-microspheres in the treatment of hepatocellular carcinoma: compared with traditional percutaneous ethanol injection: an animal studyY-Ch Lin, S-Ch Tsai, G-U Hung, et al.
Nuklearmedizin. Nuclear Medicine|May 20, 2006
Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.iG Glatting, T Kull, N M Blumstein, et al.
Nuklearmedizin. Nuclear Medicine|May 20, 2006
[Integration of PACS and HIS into the workflow of a nuclear medicine department. Experience in Regensburg]P Männer, B Tege, E Fuchs, et al.
Nuklearmedizin. Nuclear Medicine|May 27, 2010
IBZM SPECT and FDG PET in the differential diagnosis of Parkinsonian syndromes: comparison with respect to inter-rater agreementT Derlin, W Afzal, F Wilke, et al.
Nuklearmedizin. Nuclear Medicine|May 28, 2010
Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trialBurkhard Riemann, J A Krämer, K W Schmid, et al.
Pageof 204